Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
| Program (Cell Type) | Indication | CAR Target(s) | Research | Preclinical | Phase 1 | Partner |
|---|---|---|---|---|---|---|
| Oncology | ||||||
| FT576 (iNK) | Multiple Myeloma | BCMA |
|
|||
| FT522 (iNK) | B-Cell Lymphoma | CD19, 41BB |
|
|||
| FT819 (iT) | B-Cell Malignancies | CD19 |
|
|||
| FT825 (iT) | Solid tumors | HER2 |
|
|||
| Undisclosed | Solid tumors | Undisclosed |
|
 |
||
| Autoimmune Disorders | ||||||
| FT522 (iNK) | Undisclosed | CD19, 41BB |
|
|||
Oncology
| Program | Indication | CAR Targert(s) | Phase |
|---|---|---|---|
| FT576 (iNK) | Multiple Myeloma | BCMA | Ph 1 |
| FT222 (iNK) | B-Cell Lymphoma | CD19, 41BB | PreClin |
| FT819 (iT) | B-Cell Malignancies | CD19 | Ph 1 |
| FT825 (iT) | Solid tumors | HER2 | PreClin |
| Undisclosed | Solid tumors | Undisclosed | Research |
Autoimmune Disorders
| Program | Indication | CAR Target(s) | Phase |
|---|---|---|---|
| FT222 (iNK) | Undisclosed | CD19, 41BB | Preclin |
iPSC = induced pluripotent stem cell iNK = iPSC-derived NK Cell iT = iPSC-derived T cell CAR = chimeric antigen receptor
